Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.66 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.66 |
| ▸ | ITGAL | P20701 | 20/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20911446 | 1.00 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22685858 | 0.93 | ITGB2 (0.75) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22685859 | 0.93 | ITGB2 (0.75) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4546545 | 0.93 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL31021036 | 0.93 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22464900 | 0.90 | ITGB2 (0.72) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22464902 | 0.90 | ITGB2 (0.72) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833730 | 0.88 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL14679347 | 0.85 | ITGB2 (0.55) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL21425560 | 0.84 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246862-B2 | Process for the preparation of lifitegrast | MANKIND PHARMA LTD. (IN) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246862-B2 | Process for the preparation of lifitegrast | LIFR, PTGFR, CSF1R | ITGB2 839/4885ICAM1 4016/4885ITGAL 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.